SEGMENT INFORMATION (Tables)

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Schedule of Net Loss of Significant Expense

The following table presents segment revenue and significant expenses regularly reviewed by the CODM for the three and six months ended June 30, 2025 and 2024:

	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2025		2024		2025		2024
Royalty revenues	$	69	$	198	$	271	$	296
Operating expenses
Research and development:
Repibresib (VYN201)	2,464		4,529		5,041		6,426
VYN202	1,667		1,895		4,184		2,901
Other segment items*	750		882		1,779		1,687
General and administrative	2,730		3,288		6,005		7,058
Total operating expenses	7,611		10,594		17,009		18,072
Operating loss	(7,542)		(10,396)		(16,738)		(17,776)
Other income, net	1,795		1,001		2,388		2,140
Loss from continuing operations before income taxes	(5,747)		(9,395)		(14,350)		(15,636)
Income tax expense	—		—		—		—
Loss from continuing operations	(5,747)		(9,395)		(14,350)		(15,636)
Loss from discontinued operations, net of income taxes	(8)		(11)		(16)		(19)
Net loss	$	(5,755)	$	(9,406)	$	(14,366)	$	(15,655)

*Other segment items relate to research and development expenses that cannot be directly allocated to one specific product candidate, such as employee-related expenses, consulting, quality control, regulatory, and general IP legal expenses.